General oncology: benign and malignant tumors. Classification. Cancerogenesis. Markéta Hermanová Neoplasia, tumor - definition n„abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of the normal tissues and persists after cessation of the stimuli which evoked the change“ (Willis) n nGenetic and regulatory changes →functional dysregulation of proliferation that becomes autonomous + failure of the process of natural cell death n n Clonal proliferation/expansion of the transformed cell n (tumors are monoclonal) n nSporadic mutations in somatic cell or germline mutations n n n Carcinogenesis nMultistep process at both phenotypic and genetic levels n nNonlethal genetic damage (or mutation) n - exogenic factors (radiation, chemicals, viruses,…) n - endogenic factors (toxic radicals, genome instability, failure of n DNA damage repair, chromosomal rearrangements,…) n - germline mutations n nClonal expansion of a single precursor cell that has incurred the genetic damage (tumors are monoclonal) n Targets of genetic damage nThe growth-promoting protooncogenes n(dominant; support of cell proliferation) nThe growth-inhibiting tumor suppressor genes n(recessive; inhibition of growth) -Gatekeepers (p53, RB) -Caretakers (genes involved in maintenance of genome integrity and DNA repair) nGenes regulating he programmed cell death (apoptosis) nGenes involved in DNA repair nOncogenic microRNA Molecular basis of cancer onkol The role of tumor suppressor p53 Composition of tumors: nParenchyma (proliferating neoplastic cells) nStroma (connective tissue and blood vessels, source of mediators promoting the tumor growth and angiogenesis) n(Cancer stem cells – tumor initiating cells) n n nCross-talk between stroma and parenchyma nTumors with abundant parenchyma: soft and flashy nTumors with abundant collagenous stroma – with desmoplastic stroma: stony hard - scirrhous Cancer stem cells – tumor initiating cells nsubpopulation of tumor cells that possess self-renewal properties and are able to differentiate into multiple cell types providing various cell lines, which enable the progression of an incipient tumor n nresistent to conventional therapies n na source of the tumor relapse after eradication of the bulk of the tumor n noncological research focused in further understanding of CSCs and in the development of terapeutic strategies targeted at CSCs. • origin scs therapy 2 Cancer stem cell therapy n Feature Benign tumors Malignant tumors Growth rate slow Relatively rapid Mitoses Infrequent Frequent and often atypical Differentiation Good Variable, often poor Nuclear morphology Often normal Usually hyperchromatic, irregular outline, multiple nucleoli and pleomorphic Invasion No Yes Metastases Never Frequent Border Often circumscribed or encapsulated Often poorly defined, irregular Necrosis Rare Common Ulceration Rare Common on skin and serous surfaces Growth on skin or mucosal surfaces Often exophytic Often endophytic Classification of tumors (1): nBenign tumors 1.Suffix –oma (fibroma, chondroma, adenoma, papilloma, cystadenoma,…) 2.Well differentiated (usually organoid – structure of benign tumors with expressed morphological (and functional respectively) similarity of tissue of origin) 3.Usually encapsulated 4.Usually cohesive, expansivelly and slowly growing well-demarcated masses (surrounding tissue often with signs of pressure atrophy); usually easy surgical removal 5.Usually no invasion or infiltration of the surrounding tissue 6.No metastases Classification of tumors (2): nMalignant tumors (malignant epithelial tumors – carcinomas, malignant mesenchymal tumors – sarcomas,….) 1.Loss of differentiation (different levels-tumor well, moderately and poorly differentiated) 2.Locally invasive, poorly demarcated, infiltrating the surrounding tissue 3.Metastases (tumor implants discontinuous with the primary tumor) Semimalignant and potentially malignant tumors nDifferent levels of loss of differentiation nTissue and cellular atypia nUsually increased proliferation, atypical mitoses nInvasive, poorly demarcated; sometimes partially expansivelly growing nNo metastases nBasalioma of the skin nDifferentiated nNo tissue and cellular atypia nNo atypical mitoses nExpansivelly growing, often encapsulated nSometimes metastases nPleomorphic adenoma of salivary glands Comparison between benign leiomyoma and malignant leiomyosarcoma Differentiation nThe extent to which neoplastic cells resemble comparable normal cells, both morphologically and functionally nAnaplasia: lack of differentiation (tumor parenchyma resembles the tissues of embryonal organs) n nPleomorphism (variation of cells and nuclei in size and in shape) nIncreased size of nuclei nNuclear atypia (hyperchromasie due to the abundance of DNA, increased N/C ration (nucleus-to-cytoplasm ratio) nIncreased number and size of nucleoli nTumor giant cells nIncreased proliferation – mitoses (atypical, bizarre mitotic figures in malignant tumors) nLoss of polarity nBasophilic cytoplasm n Grading of pancreatic ductal adenocarcinoma Grade Glandular structure Mitoses (per 10 HPF) Nuclear structure Well differentiated (I) - well differentiated tubular or duct-like structures; mucin secreting columnar cells in single layers or papillary projections - desmoplastic stromal reaction <5 slight pleomorphism, small nucleolus Moderately differentiated (II) - moderately differentiated ductal, tubular, microglandular, cribriform structures - irregular mucin production 6-10 conspicious pleomorphism and nucleoli Poorly differentiated (III) - poorly differentiated glandular structures, mucoepidermoid and pleomorphic, undif. structures - abortive mucin production >10 pronounced pleomorphism, enlarged nuclei and prominent nucleoli •+ grade IV: undifferentiated tumor Well differentiated vs poorly differentiated pancreatic ductal adenocarcinoma •WD •PD Metastases nBenign tumors do not metastasize nInvasiveness of malignant tumor enables metastatic spreading n nThree pathways of metastatic spreading: 1.Hematogenous spread 2.Lymphatic spread (especially in carcinomas; sentinel lymph node) 3.Direct seeding of body cavities or surfaces (implantation on serous surfaces (peritoneum, pleura, pericardium), on mucosal layers of tubular organs , withinjoint space, in subarachnoid space, ….) 4. n Genetic predisposition to cancer nAD inherited cancer syndromes (inherited mutation in a single allele of a tumor suppressor gene; the second hit in somatic cells): 1.RB tumor suppressor gene (childhood retinoblastoma) 2.APC tumor suppressor gene (familial adenomatous polyposis) 3.p53 tumor suppressor gene (Li-Fraumeni syndrome) n(MEN 1, 2; NF1,2; p16; BRCA1, 2; VHL; Peutz-Jeghers sy,….) n nDefective DNA repair syndromes (AD) n (hereditary nonpolypoid colon cancer (Lynch sy); MSH2, MSH6, MLH1) n nFamilial cancer (breast, pancreas, ovary) n nAR inherited cancer syndromes (defective DNA repair, genetic instability; Fanconi anemia, ataxia teleangiectasia, xeroderma pigmentosum,…) n nInteractions between genetic and epi-genetic factors 1. 1. Nonhereditary predisposing conditions nChronic inflammation and cancer n nPrecancerous conditions -Adenomatous polyps of colon -CIN, VIN, EIN, PanIN, PIN, -Atypical ductal or lobular hyperplasia n Dysplasia nIn epithelia n nA loss of uniformity of the individual cells as well as loss in their architectural orientation n nLow grade vs high grade dysplasia n nIntraepithelial neoplasia/dysplasia n nDysplastic changes can involve the entire thickness of the epithelium – preinvasive neoplasm – carcinoma in situ 10_01B •Carcinoma in situ 19 •CIN III The role of inflammation in carcinogenesis nproduction of reactive oxygen species (ROS), cytokine release, and upregulation of pro-inflammatory transcription factors nMediators of the inflammatory pathways (e.g., NF-κB, COX-2, 5-LOX, IL-8,…): -induce genetic damage -promote cell proliferation -inhibit apoptosis -regulate the tumor associated angiogenesis Relationship between inflammation and cancer. nIBD – colorectal cancer nHelicobacter pylori chronic gastritis – gastric cancer nchronic viral hepatitis – hepacellular carcinoma nesophagitis (Barret´s esophagus) – esophageal carcinoma nliver fluke infection – cholangiocellular carcinoma nchronic pancreatitis – pancreatic cancer Pancreatic intraepithelial neoplasms (PanIN): microscopic precursor of pancreatic ductal adenocarcinoma. nPanIN-1A nPanIN-1B nPanIN-2 nPanIN-3 n panin PanIN: non-invasive intraductal epithelial proliferation Oncogenesis of pancreatic ductal adenocarcinoma: current accepted linear model of progression. nActivation of oncogenes n KRAS, MYB, AKT2, AIB1 nInactivation of tumor suppressor genes n p16, TP53, DPC4, BRCA2, LKB1/STK11 nDNA Mismatch Repair n MSH2, MLH1,…. nEpigenetic alterations, dysregulation of oncoproteins, activation of Hedgehog and Notch signalling pathways n n •Hruban et al. Progression model of pancreatic cancer. Clin Cancer Res 2000; 6: 2969-2972. PanIN lesions: low grade vs high grade PANIN_86 PANIN_29 PANIN_19 PANIN_42 •PanIN 1A •PanIN 2 •PanIN 3 •PanIN 1B Histogenetic classification of tumors nEpithelial tumors nMesenchymal tumors nNeuroectodermal tumors nGerminal tumors nMixed tumors Principal characteristics of carcinomas and sarcomas Feature Carcinoma Sarcoma Origin Epithelium Connective/mesenchymal tissue Behaviour Malignant Malignant Frequency Common Relatively rare Preferred route of metastasis Lymph (into lymph nodes) Blood (into liver, bones, brain,…..) In situ phase Yes No Age group Usually over 50 years Usually bellow 50 years Epithelial tumors Epithelium Benign Malignant Squamous Squamous cell papilloma Squamous cell carcinoma Transitional Transitional cell papilloma Transitional cell carcinoma Basal cell Basal cell papilloma Basal cell carcinoma Glandular Adenoma Adenocarcinoma spinaliom01 papilom01 •Squamous cell carcinoma •Papillocarcinoma spinaliom03 spinaliom04 •Keratinisation, mitoses in SCC •Intercellular bridges- tonofilaments Poorly differentiated carcinoma, mitoses _colon-polyps-1-387n _s5-12-tub-adenom-2x-he •Adenomatous polyps of large intestine •Tubular adenoma, low grade dysplasia _s4-5-carc-10x-he mucinca02 •Adenokarcinoma, intestinal type •Adenocarcinoma – gelatinous, mucinous Mesenchymal tumors Tissue of origin Benign Malignant Smooth muscle Leiomyoma Leiomyosarcoma Striated muscle Rhabdomyoma Rhabdomyosarco-ma Adipose tissue Lipoma Liposarcoma Blood vessels Angioma Angiosarcoma Bone Osteoma Osteosarcoma Cartilage Chondroma Chondrosarcoma Germ cell tumors nDerived from germ cells n nSomatic differentiation (teratomas – mature, immature) n nExtrasomatic differentiation (chorioncarcinoma, yolk sack tumor) n ntestis, ovary + extragonadal germ cell tumors in mediastinum, retroperitoneum, epiphyseal region , sacrococcygeal localisation,… n Primitive germ cell of origin •Differentiation of primitive cell along the gonadal line •(gonocyte, spermatogonia), without developed differentiation potencies •- Seminoma •Totipotent cell •Undifferentiated cell •- Embryonal carcinoma •Extraembryonally differentiated - Yolk sack tumor - Chorioncarcinoma •Intraembryonally differentiated •Teratoma (mature, immature, with malignant •transformation of somatic elements) •- (Polyembryoma) •Histogenesis of germ cell tumors -Seminoma (dysgerminoma) -Spermatocytic seminoma -Embryonal carcinoma -Yolk sack tumor -Polyembryoma -Chorioncarcinoma -Teratoma (differentiated mature, differentiated immature, with malignant transformation) n nMixed germ cell tumor (40 %) n nOncomarkers: aFP, hCG, hPL, PLAP, CEA, LDH (detection in serum and/or tissues; diagnostics and monitoring of patients during/after a treatment) n tumor age structure oncomarker Seminoma 40-50 Solid, polygonal clear cells, stromal lymfocytic infiltration. 10 % hCG Embryonal carcinoma 20-30 Undifferentiated, pleiomorphic cells in sheets, solid, tubullary and papillary; necroses 90 % hCG and/or aFP Yolk sack tumor 3 Poorly differentiated cells, broad spectrum arrangement of cuboidal and columnar cells, glomeruloid formation 90 % aFP Chorioncarcinoma 20-30 Cytotrophoblast and syncytiotrophoblast withour villous formation, haemorhage, necroses 100 % hCG Teratoma * Tissues of 3 germ layers in various stage of differentiation 50 % hCG and/or aFP Mixed tumors 15-30 Variable presence of different components; e. g. teratoma+embryonal carcinoma 90 % hCG and/or aFP •* no age predilection •Germ cell tumors characteristics Seminoma n testis_seminoma_2 Germ cell tumors – undifferentiated: embryonal carcinoma Embryonal_carcinoma_intermed_mag 1603817-1607642-1612177-1704012 Testes_GCT_EC1 Germ cell tumors: extraembryonal differentiation Testes_GCT_ChorioCA1 Testes_GCT_YST5_SchillerDuvall m13370-95 Testes_GCT_ChorioCA5 •Choriocarcinoma •Yolk sack tumor Germ cell tumors: intraembryonal differentiation n n n Testes_GCT_ImmatureTeratoma2 F%20fel%20ovary%20teratoma%20YB59468%2005wl •Mature teratoma •Immature teratoma Extragonadal germ cell tumors (EGT) nGerm cell tumor in primary extragonadal localisation, M>F nFrom primordial germ cells? Migration failure? Localisation failure of totipotent cells? Ectopic germ cell in healthy individuals? nIn midline structures (descent tracts of germ cells into the gonadal blastema) -Diencephalopineal region, sacrococcygeal region, in anterior mediastinum, retroperitoneum,…, thymus, prostate, stomach,…… -Seminomatous and nonseminomatous, both poor and mixed -A worse prognosis; exception: EG seminoma n n Mesothelioma nPleural, peritoneum, percardium, tunica vaginalis, genital tract (benign adenomatoid tumor) nSolitary fibrous tumor – previously called benign mesothelioma n nMalignant mesothelioma 1.Epitheloid type 2.Sarcomatoid type 3.Mixed type 4. -Asbestos exposure -50 % die within 12 months Cell of origin Tumor Glial cells Astrocytoma (both low grade and high grade) Oligodendroglioma (both low grade and high grade) Glioblastoma (Ependymoma) Primitive neuroectodermal cells Medulloblastoma (CNS; central nervous system, cerebellum) Neuroblastoma (PNS; peripheral nervous system, adrenals) Retinoblastoma …..all mentioned are pediatric tumors Arachnoidal cells Meningioma Nerve sheath cells Schwannoma, neurofibroma Malignant schwannoma, neurofibrosarcoma ANS; autonomous nervous system Paragangliomas, chemodectomas, pheochromocytoma •+ secondary, metastatic tumors CNS tumors nClinicopathological features: nCNS tumors do not metastasise to othe organs - (only infiltration of adjacent tissues and spreading through - CSF pathways) nLocal effects -Signs related to the site of the tumor -e.g. epilepsy with a temporal lobe tumor, paraplegis in spinal cord tumor nMass effects -Signs and symptoms of space occupying lesions -Vasogenic oedema around CNS tumor -Herniation -Hydrocephalus in posterior fossa tumor Diagnosis of neoplasias nEarly detection and staging important for successful treatment nThe role of screening programs in early diagnostics n nLaboratory values (incl. tumor markers), radiography, endoscopy, isotope scan, CT scan, mammography, MRI and tissue biopsy (histopathological examination (incl. molecular pathology and genetics) → tumor typing)) n •diagnostic algorithm •clinical signs •clinical examination •yes •no •diagnostic imaging techniques •(x-ray, CT, MRI,…USG,…) •suspected cancer •yes •no •exploratory biopsy •malignant tumor •benign tumor, pseudotumor •typing, grading, staging •Cancer staging → therapy •cancer suspicion Antineoplastic treatment modalities nCurative (with intent to cure) nPalliative (provides symptomatic relief but does not cure) n nSurgical treatment (in solid tumors with a goal of total resection) nAdjuvant therapies: -Irradiation therapy -Chemotherapy (especially effective in hematooncological malignancies) -Immunotherapy -Hormonal therapy (breast, prostate) -Targeted therapy (biologic therapy); individualized, personalized -Hematopoietic cell transplantation - n*neoadjuvant therapy n (aims to reduce the size or extent of the cancer before using radical treatment intervention) - n n n Paraneoplastic syndromes nLocal effects of tumor growth n n+paraneoplastic effects of tumors n(=signs and symptoms undirect to either primary tumor or its metastases) n n Causes of paraneoplastic syndromes nVasoactive tumor products, produced by tumor cells (e.g. serotonin, histamin, catecholamins, prostaglandins,…) n nEctopic hormone production by tumor cells (ACTH in small cell lung carcinoma,..) n nOsteolytic skeletal metastases causing hypercalcaemia n nUnidentified tumor products or circulating immune complexes (vasculitis, nephritis,…) n nProduction of autoantibodies by tumor cells (paraneoplastic polymyositis, myastenic syndrome, scleroderma,…) n n* musculoskeletal, neurologic and cutaneous manifestations are often in paraneoplastic syndromes n •Thank you for your attention…..